Price
No data yet.
Social Signal Score
Analyst Ratings
36 analystsRevenue
$524.43MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- William H. Lewis
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,664
- Beta
- 0.81
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 9.20
Financials
Revenue
$524.43M+5232.3%Net Income
$-100.32MEBITDA
$-68.85MFree Cash Flow
$-42.09MEPS (diluted)
$-0.46Shares Outstanding (diluted)
218.79M+253.1%Operating Expenses
$522.99MCash & Debt
$1.15BRevenue by Segment (annual)
$606.42MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $606.42M | $-1.28B | $-6.41 |
| 2024 | $363.71M | $-913.77M | $-5.57 |
| 2023 | $305.21M | $-749.57M | $-5.34 |
| 2022 | $245.36M | $-481.53M | $-3.91 |
| 2021 | $188.46M | $-434.65M | $-3.88 |
| 2020 | $164.41M | $-294.09M | $-3.01 |
| 2019 | $136.47M | $-254.34M | $-3.01 |
| 2018 | $9.84M | $-324.28M | $-4.22 |
| 2017 | $0.00 | $-192.65M | $-2.89 |
| 2016 | $0.00 | $-176.27M | $-2.85 |
| 2015 | $0.00 | $-118.18M | $-2.02 |
| 2014 | $11.50M | $-79.16M | $-1.84 |
| 2013 | $11.50M | $-56.07M | $-1.60 |
| 2012 | $0.00 | $-41.37M | $-1.56 |
Valuation
INSMhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+70.72%Social Signal Score
Mentions (41)
- Newsdefenseworld.net·1d ago·Neutral
Top Pharmaceutical Stocks To Add to Your Watchlist – November 19th Eli Lilly and Company, Insmed, Johnson and Johnson, Merck and Co., Inc., AbbVie, Pfizer, and SELLAS Life Sciences Group are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of companies that research, develop, manufacture, or sell prescription and other medicines. For investors, they offer exposure to
View source ↗ - News (RSS)seekingalpha·1d ago·Positive
Insmed: Maintaining Strong Buy On Commercial Execution And Takeover Interest
View source ↗ - News (Marketaux)seekingalpha.com·1d ago·Positive
Insmed: Maintaining Strong Buy On Commercial Execution And Takeover Interest Insmed Incorporated ( [+83 characters]
View source ↗ - News (RSS)barrons·2d ago·Neutral
Health Care Roundup: Market Talk Find insight on Sanofi, Insmed, Novartis and more in the latest Market Talks covering he health care sector.
View source ↗ - Newsproactiveinvestors.com·3d ago·Neutral
Insmed shares jump 18% as Sanofi weighs potential takeover Insmed Incorporated (NASDAQ:INSM) shares surged on Thursday after reports that French pharmaceutical group Sanofi is considering an acquisition of the US biotechnology company, which has a market value of about $26.28 billion. On Thursday afternoon, Insmed was trading at $141.84, up $22.04, or 18.4%.
View source ↗ - Newsbarrons.com·3d ago·Neutral
Insmed Stock Already Was Flying High. Sanofi Takeover Buzz Lights the Afterburners. Insmed stock jumps following a report saying Sanofi is eyeing a takeover of the biopharma company.
View source ↗ - Newsmarketbeat.com·5d ago·Negative
Insmed Sees BRINSUPRI Reaching $7 Billion in Peak Sales, Expects Cash-Flow Positive Year Ahead Insmed NASDAQ: INSM expects its bronchiectasis drug BRINSUPRI to generate $1.35 billion to $1.4 billion in its first full year of launch, Chief Executive Officer Will Lewis said, as the company looks to reach more patients and expand its pipeline.
View source ↗ - Newsseekingalpha.com·6d ago·Positive
Insmed Incorporated (INSM) Presents at Jefferies Global Healthcare Conference 2026 Transcript Insmed Incorporated (INSM) Presents at Jefferies Global Healthcare Conference 2026 Transcript
View source ↗ - Newsseekingalpha.com·15d ago·Neutral
Insmed: A Blockbuster Launch, Priced Ahead Of Its Own Guidance Insmed Incorporated is rated Hold, with a fair value of ~$99 versus a $110 share price, reflecting a blockbuster BRINSUPRI launch. INSM's valuation assumes BRINSUPRI sustains ~$75M quarterly sales growth for three years, exceeding the company's Q4 midpoint guidance. Key catalysts are Q4 2026 BRINSUPRI sales and the January 2027 FDA decision on ARIKAYCE's label expansion; either could shift the rating.
View source ↗ - Newsprnewswire.com·18d ago·Positive
Insmed to Present at November and December 2026 Investor Conferences BRIDGEWATER, N.J., Nov. 4, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the following investor conferences: Jefferies Global Healthcare Conference in London on Monday, November 16, 2026, at 2:00 p.m.
View source ↗ - News (RSS)seekingalpha·22d ago·Positive
Insmed Incorporated (INSM) Q3 2026 Earnings Call Transcript
View source ↗ - Newsseekingalpha.com·23d ago·Positive
Insmed Incorporated (INSM) Q3 2026 Earnings Call Transcript Insmed Incorporated ( INSM ) Q3 2026 Earnings Call October 29, 2026 8:00 AM EDT Company Participants William Lewis - President, CEO & Chairman Sara Bonstein Martina Flammer - Chief Medical Officer Conference Call Participants Yesha Patel - Evercore ISI Institutional Equities, Research Division Jessica Fye - JPMorgan Chase & Co, Research Division Faisal Khurshid - Jefferies LLC, Research Division Andrea Tan - Goldman Sachs Group, Inc., R…
View source ↗ - Newszacks.com·23d ago·Positive
INSM Q3 Earnings Miss, Stock Soars on Sales Beat & Raised Guidance Insmed's third-quarter revenues surge 268%, fueled by strong Brinsupri sales, prompting a 15% stock rally and higher 2026 sales guidance.
View source ↗ - News (RSS)fool·24d ago·Positive
Insmed (INSM) Q3 2026 Earnings Call Transcript BRINSUPRI revenue surged to $400.1 million, driving 268% total revenue growth year-over-year.
View source ↗ - Newsmarketbeat.com·24d ago·Neutral
What Insmed (INSM) Said on Its Q3 Earnings Call Insmed NASDAQ: INSM reported third-quarter 2026 revenue growth from both of its commercial respiratory products and raised the low end of its full-year revenue guidance for BRINSUPRI and ARIKAYCE.
View source ↗ - Newszacks.com·24d ago·Neutral
Insmed (INSM) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates While the top- and bottom-line numbers for Insmed (INSM) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
View source ↗ - Newszacks.com·24d ago·Negative
Insmed (INSM) Reports Q3 Loss, Tops Revenue Estimates Insmed (INSM) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to a loss of $1.75 per share a year ago.
View source ↗ - Newsprnewswire.com·24d ago·Positive
…(brensocatib hydrate) for the Treatment of Non-Cystic Fibrosis Bronchiectasis in Japan— BRIDGEWATER, N.J., Oct. 29, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today reported financial results for the third quarter ended September 30, 2026, and provided a business update.
View source ↗ - Newsprnewswire.com·33d ago·Positive
… Verily Health and Veteran Biopharma Finance Leader, Join as New Independent Directors— BRIDGEWATER, N.J., Oct. 20, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the appointment of Paul Hudson and Utpal Koppikar as independent members of its Board of Directors, effective immediately.
View source ↗ - Newsprnewswire.com·34d ago·Positive
…h Non-Cystic Fibrosis Bronchiectasis (NCFB), Is Now Available by Prescription in Japan— BRIDGEWATER, N.J., Oct. 19, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the commercial launch in Japan of BRINSUPRI ® Tablets 25 mg (brensocatib hydrate), an oral, once-daily treatment for non-cystic fibrosis bronchiect…
View source ↗ - News (RSS)investing·38d ago·Neutral
Insmed launches four phase 3 trials for lung disease therapy
View source ↗ - Newsprnewswire.com·38d ago·Neutral
…Space, With the Potential to Redefine Prostanoid Therapy for These Patient Populations— BRIDGEWATER, N.J., Oct. 15, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, will feature the global PALM Clinical Development Program at the American College of Chest Physicians® Annual Meeting 2026 (CHEST 2026), which is investigating trep…
View source ↗ - Newsprnewswire.com·39d ago·Positive
…opment in Patients With Newly Diagnosed Mycobacterium avium Complex (MAC) Lung Disease— BRIDGEWATER, N.J., Oct. 14, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced new data from its respiratory portfolio will be presented at the American College of Chest Physicians® Annual Meeting 2026 (CHEST 2026), taking plac…
View source ↗ - Newsbenzinga.com·41d ago·Negative
This Insmed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
View source ↗ - Newszacks.com·47d ago·Neutral
INSM Stock Slides on CFO Exit, Reiterates '26 Sales View Insmed shares slide after CFO Sara Bonstein's surprise exit, though the company reaffirms 2026 revenue guidance for Brinsupri and Arikayce.
View source ↗ - Newsprnewswire.com·48d ago·Positive
…uarter 2026 Financial Results Conference Call to Be Held on Thursday, October 29, 2026 — BRIDGEWATER, N.J., Oct. 5, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that Sara Bonstein will step down as Chief Financial Officer (CFO).
View source ↗ - Newszacks.com·61d ago·Neutral
FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce INSM's Arikayce label expansion gets FDA priority review, potentially broadening its use in newly diagnosed MAC lung disease.
View source ↗ - Newsseekingalpha.com·61d ago·Positive
Insmed: Expensive Stock, But Discount To Recent Highs Makes Bull Case Insmed is rated Buy, driven by Brinsupri's blockbuster launch and strong TPIP Phase 2b data. Brinsupri generated $517m in 1H 2026, faces minimal competition, and targets $7bn+ peak sales with COPD/asthma comorbidity upside. TPIP's Phase 2b results exceeded expectations; four Phase 3 indications could yield $6bn+ peak sales if approved.
View source ↗ - Newsprnewswire.com·62d ago·Negative
…arlier in Their Disease Course and Would Fulfill Post-Marketing Requirement From FDA— BRIDGEWATER, N.J., Sept. 21, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's Supplemental New Drug Application (sNDA) for review of ARIKAYCE® (amikac…
View source ↗ - News (RSS)yahoo·67d ago·Neutral
The Fund Exited Insmed (INSM) After the Investment Thesis Played Out
View source ↗ - Newsprnewswire.com·67d ago·Positive
…,350 employees to support over 50 organizations throughout the U.S., Europe, and Japan BRIDGEWATER, N.J., Sept. 16, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today holds its fifth annual Global Day of Good, a company-wide day of service during which employees volunteer simultaneously in their respective communities aroun…
View source ↗ - News (RSS)seekingalpha·68d ago·Positive
Insmed Incorporated (INSM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·69d ago·Positive
Insmed Incorporated (INSM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Insmed Incorporated (INSM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·74d ago·Positive
Insmed Incorporated (INSM) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript Insmed Incorporated (INSM) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·75d ago·Neutral
Insmed: A Strong Launch And A Much Bigger Peak Sales Opportunity Insmed is rated Strong Buy with a $175 target, offering ~39% upside from current levels. BRINSUPRI's rapid launch and raised peak sales guidance to $7B+ underpin INSM's commercial momentum and pipeline credibility. Management now estimates combined peak sales of $14B+ for its three lead drugs, up 75%, though some projections are not yet data-backed.
View source ↗ - Newsprnewswire.com·79d ago·Positive
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) BRIDGEWATER, N.J., Sept. 4, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 128 new employees.
View source ↗ - Newsprnewswire.com·80d ago·Positive
…Powder (TPIP) via COMPERA 2.0 Risk Assessment in Pulmonary Arterial Hypertension (PAH)— BRIDGEWATER, N.J., Sept. 3, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that five abstracts highlighting data from its respiratory portfolio have been accepted for presentation at the European Respiratory Society (ERS) C…
View source ↗ - News (RSS)yahoo·81d ago·Neutral
Do You Believe in Insmed’s INSM) Long-Term Potential Despite Short-Term Challenges?
View source ↗ - News (RSS)yahoo·81d ago·Negative
Insmed’s (INSM) New Drug Launch Is Reshaping The Whole Business
View source ↗ - Newsprnewswire.com·88d ago·Positive
Insmed to Present at September 2026 Investor Conferences BRIDGEWATER, N.J., Aug. 26, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the following investor conferences: 12th Annual Cantor Fitzgerald Global Healthcare Conference in New York City on Wednesday, September 9, 2026, at…
View source ↗ - Newsprnewswire.com·90d ago·Positive
…s Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage — BRIDGEWATER, N.J., Aug. 24, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved BRINSUPRI ® (brensocatib 25-mg tablet), an oral, once-daily treatment for n…
View source ↗
Earnings
Thu, Feb 18(in 3 months)
Consensus estimate $-0.30 per share
Typical surprise -20.2% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Oct 29$-0.46 vs $-0.38miss
- Thu, Aug 6$-0.06 vs $-0.67beat
- Thu, May 7$-0.76 vs $-0.96beat
- Thu, Feb 19$-1.54 vs $-1.07miss
- Thu, Oct 30$-1.75 vs $-1.33miss
- Thu, Aug 7$-1.70 vs $-1.30miss
Estimates and results for INSM via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by INSM officers and directors.
- Bought
- —
- Sold
- $73.0m
0 trades
41 trades
- Schaeffer Orlov S Nicolesold
- Schaeffer Orlov S Nicolesold
- Schaeffer Orlov S Nicolesold
- Brennan David Rsold
- Sharoky Melvin Mdsold
- Adsett Rogersold
- Flammer Martina M.d.sold
- Flammer Martina M.d.sold
59 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Josh Gottheimerhouse · NJ05 · disclosed Jul 8, 2026 (28d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Nov 18, 2025 (46d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Oct 10, 2025 (18d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Sep 12, 2025 (35d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Aug 15, 2025 (39d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Jul 17, 2025 (31d later)Buy$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed May 14, 2025 (35d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Jul 9, 2024 (18d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Jun 8, 2024 (11d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Jan 13, 2023 (38d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
